Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

NCT00176475 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped slow accrual

Conditions

Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm

Interventions

BIOLOGICAL: rituximab
BIOLOGICAL: therapeutic allogeneic lymphocytes

Sponsor

University of Medicine and Dentistry of New Jersey

Collaborators

[object Object]